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     Clinical features in ninety-two cases of mycoplasmal pneumonia during the past 
seven years, which are fourty-one percent of 226 primary atypical pneumonia cases in this 
study, are reported. Occurrence of the illness was closely retated to age of the patients; 
it was generally higher in patients under thirty years of age at all seasons. The main cli-
nical symptoms were cough, fever, rales, sputum, headache and sore throat. However, 
these common symptoms recognized in a variety of respiratory diseases were not particu-
lar to the diagnosis of mycoplasmal pneumonia, and it was often difficult to differentiate 
from pulmonary tuberculosis, chronic pneumonitis or bronchiectasis. Although a roentge-
nographic pattern characteristic of mycoplasmal pneumonia could not be recognized, the 
majority showed a "homogenous" or "flocculent" appearance. Therefore, the appropriate 
laboratory studies for isolation of the agents and/or the related serological tests have much 
importance to the diagnosis of this disease. The treatment with erythromycin seemed to 
be more effective than other antibiotics when using chest roentgenographic resolution, as 
the parameter of response.
                  INTROCUC TION 
     Many studies in the clinical response of mycoplasmal pneumonia have been reported. 
Most of the reports have been studied with respect to diagnosis, ie. isolation, serological 
test, symptoms, physical findings, chest X-ray pattern. As the result of these, it has been
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suspected that pneumonia caused by Mycoplasma . pneumoniae (M. pneumoniae) cannot 
be differentiated clinically from other causes of pneumonia (1, 2). 
      In this paper, ninety-two cases with M. pneumoniae pneumonia diagnosed and 
treated in our clinic for the past seven years were reported compared to clinical primary 
atypical pneumonia (PAP) of unknown etiology. 
              MATERIALS AND METHODS 
      When the patients were suspected of having primary atypical pneumonia they were 
investigated for the following studies according to the orders in our pneumonia card after 
hospitalization. 
     Bacteriologic studies : For 3 days after the first medical examination, specimens of 
sputum were cultured in all patients. If the patients were treated with some antibiotic 
before starting the trials, culture was performed twenty-four hours after the antibiotic the-
rapy was discontinued. If patients found it difficult to give proper specimens for the ba-
cteriologic investigation, it was collected by aspiration through the vinyl tube in Metra's 
tube from the focal region. This was done even if the patient had slight fever. 
     Usually BTB, chocolate and blood agar plates were used for common bacteriologic 
studies, but, if mycosis of the lung was suspected, SABOURAUD'S solid medium was 
also used. Each patient's sputum was also tested using ZEEHL-NEELSEN'S staining 
and cultivated in OGAWA'S medium for 3 consecutive day to comfirm the presence of 
tubercle bacilli. 
     Mycoplasmal studies : Throat swabs from the patients were inoculated on each of 
two PPLO agar plates and broths. The growth of mycoplasma was observed at intervals 
during 14 days for the development of microscopic colonies on the agar plates and for col-
our change from red to yellow which showed the alteration of PH in the broth medium. 
When mycoplasma colonies were grown, it was identified to be M. pneumoniae by CLY-
DE's paper disc diffusion method (3). The blood specimens were obtained at the first 
visit or admission of all patients, although it was not always suitable in the acute phase. 
Subsequently convalecent sera were collected on one or more occaseions about 14 or 21 days 
later. Sera were tested for complement fixing antibody. The definite evidence of recent 
infection was established by our criterea in a preceding paper (4), if briefly stated ; (a) 
An eight-fold or more rise between acute and convelecent sera, or (b) A four-fold rise, 
and reacted in a dilution of 1: 64 or greater in the convelecent complement fixing antibo-
dy titer. 
     Virologic studies : As the evidence of recent infection of a virus only, serological 
tests against influenza virus A2 and B (CF and HI), parainfluenza virus type 1 (CF), ade-
novirus type 3 and 21 (CF), echo virus type 2 and 9 (CF), coxsackie virus A type 9 and 
B type 3 (CF) were determined in all patients ; these viruses were considered to be the 
etiological agents of viral pneumonia. 
     Clinical studies ; The patient was asked about clinical symptoms, such as cough,
sputum, sore throat, nasal symptom, chest pain, fever, headache, chill, arthralgia, otalgia, 
and also examined in respect to swelling of throat and rales in chest at least once daily by 
a member of the mycoplasma group who kept records on our pneumonia card. 
      Routine laboratory studies : Erythrocyte sedimentation rates, total and differential 
leukocyte counts and cold haemagglutination tests were performed regularly once a week, 
chest roentgenograms twice a week. If it was required, c-reactive protein, mucopoly-
saccharide, lactic dehydrogenase, urinalysis, liver function tests were also determined. 
Anyone who was suspected bronchiectasis was immediately examined by bronchography 
or, if necessary, by bronchofiberscope. 
      In order to avoid a subjective view of only one doctor, roentgenographic films of 
the chest, particularly as to the point of position and pattern of the shadow, was classifi-
ed by discussion by all members of mycoplasma study group. 
                     RESULTS 
     General description of the subjects : Three hundred fifty-eight of the 21,013 pa-
tients who attended the clinic of the second department in Nagasaki University School of 
Medicine during the period March 1965 to July 1972 were suspected intially of having 
clinical primary atypical pneumonia. Of these patients, 92 had mycoplasmal pneumonia, 
134 had viral pneumonia or unknown etiologic PAP, and the remaining 132 patients, were 
diagnosed as having diseases due to other causes ; particularly pulmonary tuberculosis, 
chronic pneumonitis, mycotic pneumonia, infiltrative type of pulmonary cancer. It was 
felt that pulmonary tuberculosis was most important disease to differentiate from primary 
atypical pneumonia in Japan. 
     Age and Sex : The distribution of patients as to age is shown in Table 1. Nine-
ty-two of 226 patients who were diagnosed as having PAP were pneumonia caused by M. 
pneumoniae. That is 41% of the patients. The incidence of M. pneumoniae pneumonia 
was related more to the age group under thirty years. Fifty were males and forty-two 
were females. 
         Table 1 Age of patients with clinical primary atypical pneumonia (PAP)
                                   Cases with CF antibody rise Percentage 
 Age Total number of PAP against M. pneumoniae with for total 
                                   or without isolation PAP 
0 - 5 27 12 44 
6 - 10 40 25 63 
11 - 20 38 21 55 
21 - 30 35 17 49 
31 - 40 24 8 33 
41 - 50 29 4 14 
51 - 33 5 15 
Total 226 92 40.7
     Occurrence of the illness : The month of admission of patients with mycoplasmal 
pneumonia and the patients who had contacted influenza virus as the primary etiologic 
agent of pneumonia without secondary complication is plotted on Figure 1. The outbreak 
of primary influenza pneumonia was observed between December and March correspond-
ing to the epidemic periods of flu in Japan, but mycoplasmal pneumonia was observed 
almost equally throughout the year.
                      • MYCOPLASMAL PNEUMONIA 
                       o INFLUENZA VIRUS PNEUMONIA 
                        WITHOUT COMPLICATION
Fig. 1. Occurrence of M. pneumoniae pneumonia
     Serologic studies : The summary of serologic data is shown in Table 2. Twenty 
three of 134 mycoplasma-negative PAP demonstrated a four-fold or greater increase in anti-
body against one of viruses measured. In thirteen of these patients, it was assumed that 
these viruses played the etiologic role of pneumonia under clinical and epidemiological 
consideration. Nine of 92 patients with mycoplasmal pneumonia were noted to have four-
fold or greater rise in virus antibody. Two patients had a dual infection clinically. 
     Bacteriologic studies : In the ninety-two mycoplasmal pneumonia patients 42.4 per-
cent (23 males and 16 females) yielded M. pneumoniae. 
     A heavy growth of microorganisms was obtained in the sputum or aspirated speci-
men cultures from thirteen patients as a whole. Of eleven organisms which were isolated 
from the patients with mycoplasma-negative PAP, 5 were Diplococcus pneumoniae, 4 were 
coagulase positive Staphylococcus, one was Haemophilus influenzae and one was Stref,tococ-
cus haemolyticus. The organisms which were isolated from two patients with mycoplasmal 
pneumonia were Klebsiella aerogenes. One of these patients had been reported in detail 
as a case with suspected superinfection with M. pneumoniae and Kl. aerogenes (5). The
Table 2 Serological response of patients with clinical primary 
        atypical pneumonia (Total number 226)
                                 M. pneumoniae Total Percentage 
       Antigen positive negative positive for total 
                           (92) (134) number patients 
Mycoplasma pneumoniae 92 92 40.7 . 
Influenza virus { A 4 12 19 8.4 
               B 1 2 
Adenovirus 2 5 7 3.1 
Echovirus { 2 0 0 3 1.3 
               9 1 2 
Coxsackie virus { A 1 0 2 0.9 
               B 0 1 
Parainfluenza virus 0 1 1 0.4
Fig. 2. Sign and symptomes of patients with clinical primary atypical pneumonia
remaining twelve patients did not have the difinite clinical evidence of bacterial pneumo-
nia in spite of a predominant growth of the microorganism in culture. 
      Clinical findings : In the description of clinical symptoms, mycoplasma positive 
cases were compared withh mycoplasma negative PAP (Figure 2). 
      The majority of the patients with mycoplasma] pneumonia (97.8%) had experienced 
an attack of characteristic coughing towards morning, this persisted each morning until 
terminal stage of the illness. In 88.0 percent of these patients fever above 38°C was 
experienced during the maximal stage. Otalgia was observed in only four patients and 
redness of tympanic membrane by otologic examination was confirmed in three of these 
four. In addition, physical findings of the lung included dry rales, moist rales or both 
was detected in approximately 50 percent of these patients. Thirty-eight patients develop-
ed the illness after a few-days course of common cold symptoms including rhinorrhoea and 
sore throat. Fifty-two patients, however, suddenly started with the onset of two or more 
symptoms of cough, fever, chill and loss of appetite. Fortunatelly two patients were found 
to have shadows on the chest X-ray film in mass examination without any respiratory 
symptoms and it was confirmed after admission that these shadows were produced by M. 
pneumoniae infection. 
     Symptoms in patients with mycoplasma negative PAP were fairly similar to that of 
mycoplasmal pneumonia, although coryzal symptoms, chest pain, chills and joint pain 
presented in high incidence in negative PAP patients. 
     Laboratory studies : In one-third of the patients total leukocyte counts on admission 
were above 20,000, and this leukocytosis was maintained during the acute stage ; usually 
4 to 7 days. The majority of the remaining ranged from 4,000 to 10,000 per cu. mm. 
About one quarter of all the patients showed a neutrophilia and an increase in immature 
band forms. Erythrocyte sedimentation rates obtained on admission ranged from 8 to 128 
mm per hour, and were significantly elevated in the majority of the patients. The shifting 
of the erythrocyte sedimentation rates and c-reactive protein were relatively reflected in 
the course of the illness. Serum cold haemagglutinin presented in 70.7 percent of the 92 
mycoplasma positive PAP and in 28.4 percent of 134 mycoplasma negative PAP. It seem-
ed clinically advisable that serum cold haemagglutination tests should be performed to 
confirm the diagnosis of mycoplasmal pneumonia. 
     Chest roentgenogram : The central area of chest roentgenographic involvement in 
the patients with mycoplasmal pneumonia is marked with a black dot in Figure 3. The 
number of dots is seen most in the right lower lung field, followed by the left lower and 
the right upper. Further, in about 90 percent of the patients the shadow on the films 
made in the antero-posterior position was confined to one lung field, but the remainder 
extended to two or more lung fields ; mostly unilateral middle and lower fields or bilateral 
hilus. In the lateral view, the most frequent shadow was located along the bronchus from 
hilus. It was also frequently located at S4, S5, and S8, Sio in right side and Sio in left 
side in the pulmonary segment. 
     When shadows were assorted by CRYSLER'S classification (7) based on the roent-
genographic characteristics of the patients with primary atypical pneumonia, 43.4 percent 
of all patients occupied a "homogenous" pattern, 40.8 percent a "flocculent or dense 
structural" and 15.8 percent a "homogeneous flocculent" (Table 3.). This percentage 
was just similar to CRYSLER'S results. of ail patients, atelectasis occured in 7 patients 
and pleural effusion in 2 patients. 
     Effects of antibiotics : It is well known that M. bneumoniae is sensitive to erythro-
mycine, tetracyclines and chloramphenicol but resistant to cephalosporin C derivate or peni-
cillin. If the patient was suspected to have clinical. PAP, one or more of the following 
antibiotics were chosen by the physician in charge. 
     a) a macrolide derivate, mostly erythromycine 1.2 g daily, three times, orally. 
     b) tetracycline 1.2 g daily, three times, orally. 
     c) chloramphenicol 1.5 g daily, three times, orally. 
     d) tetracycline 1.2 g + erythromycine 1.2 g daily, three times, orally. 
     e) aminobenzyl-penicillin 1.5 g or cephalexin 2.0 g daily, twice, orally. 
     f) conservative therapy without antibiotics.
           only main shadow was marked in the case 
                       of both involved 
     Fig. 3. Position of chest roentgenographic Shadow in 
              the patients with mycoplasmal pneumonia 
Table 3 Chest roentgenographic pattern by Crysler's classification
Homo- Homogeneous I Cotton Flocculent Flocculent Dense Homo-
geneous with wool with structural geneous 
         structural structural accentuation flocculent 
         accentuation accentuation 
22.4% 9.2% 11.8% 10.5% 1'0.5% 19.7% 15.8% 
         43.4% 40.8 % 15.8% 
       'k(46 .4%) (39.7%) (13.9%) 
    indicated the result by Crysler
Fig. 4. Persistence of the shadow after treatment start 
Table 4 Frequency of mycoplasmal pneumonia in primary 
       atypical pneumonia (by Kitamoto, 1970)
  patients number of percentage 
  age patients against period tested method country reporter 
           with PAP PAP 
 university 119* 22 1953 -60 FA U .S.A. Evans  students 
 adults 429* 3 1962-63 CF U.S.A. Muf son 
 all ages 320* 33 1961-66 FA Holland Hers 
   ~~ 112* 10 1962 CF England Goodburn 
   ~~ 246* 16 1962-63 CF Finland Jansen 
   ~~ 107* 33 1962-63 CF Sweden Biberfeld 
   ~~ 63* 38 1962-64 CF England Andrews 
   ~~ 360* 12 1963-64 CF U .S.A. Alexander 
   ~~ 164* 11 1964-65 - Germany Witzleb 
--- - ------------ ------ ------ ----------------------- -- --------------------------------------------------------- 
.... ....................... ---------------
mainly children 1445 1.8-28.1 1967-68 CF Japan Niitsu 
 adults 97 37 1947-59 FA U.S.A. Cook 
 all ages - 30-60 1957-61 - U.S.A. Parrot 
   ~i 215 20 1962-63 FA U . S . A . Grayston 
   ~~ 639 37 1963-68 CF Japan Kitamoto 
   ~~ 84 27 1964-66 CF Japan Masuda 
   ~~ 226 41 1965-72 CF Japan Hara 
  *These subjects included the patients with purulent pneumonia
The doses mentioned above correspond to the adult, it is variated with or by individual 
patient response. As a rule, these antibiotics were administered under strict attention up 
to 1 week after the clearing of the shadow on X ray film. 
      One patient suspected of having an infection with M. pneumoniae and Kl. aerogenes 
was excluded from this study because of the use of some other antibiotics. Of the ninety-
one patients, as noted in Figure 4, 30 were treated with a macrolide derivate, 28 with 
tetracycline, 5 with chloramphenicol, 8 with a macrolide derivate plus t.etrac3 cline and 8 
with aminobenzyl-penicillin or cephalexin. Twelve patients were treated with only some 
sedative but not with antibiotics. 
     In order to compare the effect of each antibiotic for mycoplasmal pneumonia the 
shadow presented in the beginning of the treatment was observed according to the method 
described by RASCH et al (8). The persistence of the shadow even after treatment was 
prolonged from the shortest treatment group with macrolide derivate as well as with macro-
lide plus tetracyclin to the longest treatment groups with aminobenzyl-penicillin or cepha-
lexin. The antibiotic-free group was situated between these two. A majority of patients 
treated with aminobenzyl-penicillin or cephalexin were initially considered to have bacteri-
al pneumonia and were referred to our clinic in the final stage of the illness. 
                         DISCUSSION 
     It has been nearly a decade, since the name Mycoplasma pneumoniae was given to 
an organism thought to be the etiologic agent of primary atypical pneumonia (9). The 
research of clinical and epidemiological nature of this mycoplasmal infection, of course, 
has been supported by the experimental observation of volunteers made by CHANOCK 
(10) and RIFKIND (6). 
     It is well known that the pattern of M' pneumoniae infection is endemic (11,12,13) , 
not pandemic, and therefore intimate and prolonged contact is required (1, 14). This 
was recognized to be the infection among small groups of people such as families (15 - 22), 
military recruits (23) or submarine crews (24). Such epidemiological problems including 
occurence of the endemic, reinfection and carrier state of the mycoplasmosis has been dis-
cussed too, by us, previously (4). At this time, the clinical features of ninety-two cases 
suffering from M. Pneumoniae pneumonia were described. 
     The patient with mycoplasmal pneumonia occupied between 1.8% and 60 % of pa-
tients with primary atypical pneumonia as shown Table 4, which was summarized by KI-
TAMOTO (25). Although our results were situated in a high position, it was consider-
ed that this frequency would be changeable depending upon the method of the investiga-
tion or the existence of the prevalence, and so forth. 
     The clinical illness caused by this organism is usually called primary atypical pneu-
monia. However, CHANOCK et al has stated some characteristics of mycoplasmal 
pneumonia (26) : it generally has (a) a longer incubation interval (2-3 weeks) , (b) longer 
duration if untreated, (c) more headache and earache, (d) less coryza, (e) rales in approxi-
mately 50 to 80 percent of patients. In our data, the incubation period could not exactly 
be proved, because the patients were attending an out-patients clinic. Surely the coryza 
symptom was less in the mycoplasmal patients than the mycoplasma negative patients and 
moist rales in more than half cases was observed in. 51 percent of the patients. C uVllv er" 
sely, headache and earache showed a same percentage in mycoplasma positive and negative 
PAP. Cough occured in about 98 percent of patients persisted until terminal stage of the 
illness as described by KINGSTON (27). 
     The roentgenographic findings in the patients diagnosed as mycoplasmal pneumonia 
have been reported (29-33). However, when the abnormal pulmonary X-ray findings seen 
in the patient with mycoplasmal pneumonia were compared with those observed in myco-
plasma negative pneumonia (28) and with those observed in usually called primary atypical 
pneumonia reported by CRYSLER, they had almost similar incidence. Therefore, it 
could be stated that pulmonary roentgenographic pattern in the patients caused by the 
organism cannot be differentiated from that of patients by other etiologic agents as noted 
by GEORGE, HEBERT and ZWAD (29, 30, 32). Although small. number of the 
patients had evidence of roentgenographic findings of atelectasis or pleural effusion it was 
reported that these were not peculiar findings to mycoplasmal pneumonia (29, 30, 31). 
     As the patients suffering from the pneumonia caused by M. pneumoniae were not 
treated by double blind method, the effect of antibiotics for this disease may not always 
reflect true evaluation. Yet, macrolide derivates mainly erythromycin, alone or combined 
with tetracycline resolved the abnormal shadow in the shortest stage averaging about 12.5 
days. Contrarily, the average time required for roentgenographic clearing was 17.4 days 
in untreated group and 22.6 days in the treated group with aminobenzyl-peniclilin or ce-
phalexin although this group included many severe cases. It was observed by SMITH et 
al that the organism was not eradicated by therapeutic doses of erythromycin or tetracyc-
line (34). Experimental studies by us in the hamster showed that the organism remained 
in the lungs for as long as 16 days in spite of treatment with erythromycin or tetracycline 
(35). Similar results were reported by SLOTKIN (36) in a study for prophylactic approach 
in vivo and in vitro. Our results in clinical treatment corresponded to the results in vitro 
as did the report by RASCH et al (8) and KINGSTON et al (27), but the determination 
of effect in the treatment with antibiotics for mycoplasmal pneumonia due to the roentge-
nographic resolution could not be correlated to that due to the eradication of the organism.
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